Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial

Author:

Cheng Ran1234,Taleb Nadine156ORCID,Wu Zekai17,Bouchard Delphine1,Parent Valérie1,Lalanne-Mistrih Marie-Laure1,Boudreau Valérie1,Messier Virginie1,Lacombe Marie-Josée1,Grou Caroline1,Brazeau Anne-Sophie18ORCID,Rabasa-Lhoret Rémi125910ORCID

Affiliation:

1. 1Institut de recherches cliniques de Montréal, Montréal, Québec, Canada

2. 2Department of Biomedical Sciences, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada

3. 3Endocrinology Division, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada

4. 4Endocrinology Division, Hôpital Santa-Cabrini, Montréal, Québec, Canada

5. 5Endocrinology Division, Centre hospitalier de l’Université de Montréal, Montréal, Québec, Canada

6. 6Centre de recherche du Centre hospitalier de l’Université de Montréal, Montréal, Québec, Canada

7. 7Experimental Medicine Division, Faculty of Medicine, McGill University, Montréal, Québec, Canada

8. 8School of Human Nutrition, McGill University, Montréal, Québec, Canada

9. 9Department of Nutrition, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada

10. 10Montreal Diabetes Research Center, Montréal, Québec, Canada

Abstract

OBJECTIVE Current guidelines recommend initiating treatment for nonsevere (NS) hypoglycemia with 15 g carbohydrates (CHO) at 15-min intervals when blood glucose (BG) reaches <70 mg/dL (3.9 mmol/L). Despite this recommendation, NS hypoglycemia management remains challenging for individuals living with type 1 diabetes (T1D). We aimed to assess the efficacy of 15 g CHO at higher BG levels. RESEARCH DESIGN AND METHODS A total of 29 individuals with T1D participated in an open-label crossover study. After an inpatient subcutaneous insulin-induced decrease in BG in the fasting state, 16 g CHO was administered orally at a plasma glucose (PG) of <70 (3.9), ≤80 (4.5), or ≤90 mg/dL (5.0 mmol/L). The primary outcome was time spent in hypoglycemia (<70 mg/dL) after initial CHO intake. RESULTS When comparing the <70 (control) with the ≤80 and ≤90 mg/dL treatment groups, 100 vs. 86 (P = 0.1201) vs. 34% (P < 0.0001) of participants reached hypoglycemia, respectively. These hypoglycemic events lasted 26.0 ± 12.6 vs. 17.9 ± 14.7 (P = 0.026) vs. 7.1 ± 11.8 min (P = 0.002), with a PG nadir of 56.57 ± 9.91 vs. 63.60 ± 7.93 (P = 0.008) vs. 73.51 ± 9.37 mg/dL (P = 0.002), respectively. In the control group, 69% of participants required more than one treatment to reach or maintain normoglycemia (≥70 mg/dL), compared with 52% in the ≤80 mg/dL group and 31% in the ≤90 mg/dL group, with no significant rebound hyperglycemia (>180 mg/dL) within the first hour. CONCLUSIONS For some impending NS hypoglycemia episodes, individuals with TID could benefit from CHO intake at a higher BG level.

Funder

Juvenile Diabetes Research Foundation Canada

Canadian Institutes of Health Research

Publisher

American Diabetes Association

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3